Actively Recruiting
Optimal Non-invasive Brain Stimulation for Peripheral Vision
Led by The Hong Kong Polytechnic University · Updated on 2024-10-29
40
Participants Needed
1
Research Sites
200 weeks
Total Duration
On this page
Sponsors
T
The Hong Kong Polytechnic University
Lead Sponsor
C
Chinese University of Hong Kong
Collaborating Sponsor
AI-Summary
What this Trial Is About
Glaucoma is a complex disease that can result in progressive vision loss. There are no treatments that restore vision lost to glaucoma. However, recent studies have shown that vision can be improved by non-invasive brain (NIBS) stimulation and visual training. In this study, we aim to compare and find out the optimal non-invasive brain stimulation model (transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), and transcranial random noise stimulation (tRNS)) for improving peripheral vision in glaucoma patients. The proposed treatment is the application of transcranial electrical stimulation (tES) onto the participant's head, with brain stimulation aimed at the Primary Visual Cortex toward the occipital pole. The investigators hypothesize that the tES will enable higher performance in the reading task and secondary measures due to an increase in the cortical excitability of the stimulated brain cells, and tRNS will generate the greatest acute improvement in peripheral vision than either a-tDCS, tACS, or sham stimulation.
CONDITIONS
Official Title
Optimal Non-invasive Brain Stimulation for Peripheral Vision
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years
- Diagnosis of primary open angle or normal tension glaucoma with relative scotoma in both eyes
- Relative scotoma with Humphrey Field Analyser threshold perimetry loss (mean deviation 4-6dB) within central 30�b0 of visual field in at least one eye
- Best-corrected distance visual acuity of 6/12 or better (0.3 logMAR or better)
- Stable vision and visual field loss for at least 3 months
- Cognitive functional score of 22 or above on the Montreal Cognitive Assessment - Hong Kong version (HK-MoCA)
You will not qualify if you...
- Ocular diseases other than glaucoma (e.g., age-related macular degeneration, diabetic retinopathy, moderate to severe cataract) or severe hearing impairment
- Severe medical problems such as stroke or Parkinson's disease
- Self-reported neurological conditions like brain surgery, brain tumor, or peripheral neuropathy, or cognitive disorders including diagnosed dementia or cognitive impairment
- Vestibular or cerebellar dysfunction or history of vertigo
- Use of medications for neurological conditions or psychiatric drugs that might affect motor control
- Contraindications for non-invasive brain stimulation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Allen MY Cheong
Hong Kong, China
Actively Recruiting
Research Team
A
Allen Cheong, PhD
CONTACT
B
Ben Thompson, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here